ABSTRACT
On April 3, 2020, Rishi Bhargav, Chief Executive Officer of Ashian Biotech, held a videoconference with his senior management team to discuss the company's future. Lately, he had been under fire from the company's board for not pursuing new opportunities aggressively. Krish Rao, Ashian's founder and chairman, had told Rishi that the board might not renew Rishi's three-year contract, which was coming to an end in December 2020, if the growth plans continued to disappoint them.
